Our commitment to transparency
GSK, like most other innovative pharmaceutical companies, engages with healthcare professionals (HCPs) who are considered experts in their field. We believe that it is appropriate to compensate healthcare professionals for their time and investment.
Globally, GSK is committed to building transparency in our operations because it enhances trust and value for patients and our healthcare system. Transparent scientific dialogue and engagement with experts is in the interests of all those working to develop new medicines and improve clinical practice and care for patients.
We are pioneers
GSK and ViiV Healthcare initiated voluntary disclosure of aggregate payments made to HCPs and HCOs in 2017. We have since expanded reporting to include payments to individual HCPs and HCP professional corporations.
The important relationship between industry and HCPs
The relationship between healthcare companies and HCPs is an essential part of patient care, disease understanding, as well as the research and discovery of innovative medicines in Canada. By continuing to be transparent on these relationships, we are evolving with society’s expectations.
In Scope Activities
GSK engages with HCPs and HCOs to foster scientific exchange, which benefits patients. These interactions are governed by law and regulated by Innovative Medicines Canada’s Code of Ethical Practices (PDF - 1.7 MB).
What are payments or transfers of value (TOV)?
They are payments or contributions made to HCPs (directly or via a professional corporation) or HCOs. HCOs are any private or public sector organization, institution or association that is comprised of HCPs and/or that provides healthcare services, and also includes a clinic or medical practice consisting of one or more HCPs.
What are the collaborations for?
- Grants to HCOs
- Training activities and scientific professional meetings
- R&D activities
- Provision of services such as consulting
What does individual disclosure mean?
We are disclosing total payments made to individual HCPs. This includes payments made directly to an HCP for services, which include speaker fees, honoraria, consultations, advisory boards, as well as indirect payments, such as reimbursement of travel or accommodation associated with those services and virtual registration fees. Additionally, payments made to HCP professional corporations will be disclosed under the name of the professional corporation.
Of note, payments do not include where an HCP has withdrawn their consent to disclose this information.
